Colorectal cancer screening saves lives. That is not a slogan. Randomized trials and decades of observational data support it. But the screening landscape is confusing. You have probably heard of colonoscopy. You may have seen Cologuard ads on television. Your doctor may have handed you a FIT kit and told you to mail in a stool sample. These tests are not interchangeable. They look for different things, at different sensitivities, on different timelines, and the follow-up implications when a result comes back positive are not the same. This article explains what each test actually does, how well it works, and how current guidelines suggest choosing among them.
What is a FIT test and how does it screen for colorectal cancer?
The fecal immunochemical test (FIT) is the most widely used stool-based screening test worldwide. It uses antibodies to detect human hemoglobin (blood) in your stool. The logic is straightforward: colorectal cancers and many large polyps bleed, and that blood ends up in stool. FIT detects it even when the amount is too small to see with your eyes.
FIT is simple. You collect a small stool sample at home using a kit, typically by brushing the surface of a bowel movement with a small probe, placing it in a collection tube, and mailing it to a lab. No dietary restrictions, no bowel prep, no sedation, no time off work. Results come back as positive or negative.
In a large meta-analysis published in Annals of Internal Medicine (Lee et al., 2014), FIT had a pooled sensitivity of approximately 79% for colorectal cancer (ranging from about 74% to 92% depending on the specific test brand and cut-off threshold used). For advanced adenomas (large precancerous polyps), sensitivity is considerably lower, around 24%. Specificity is high, approximately 94 to 96%, meaning false positives are relatively uncommon.
The critical detail: FIT is designed to be repeated annually. A single FIT catches about 74% of cancers. But because cancers and large polyps tend to bleed intermittently, annual testing over multiple years significantly increases the cumulative probability of detection. Modeling studies suggest that annual FIT over 10 years detects a comparable proportion of cancers to a single colonoscopy, though it does not match colonoscopy for polyp detection and removal.
âšī¸FIT replaced the older guaiac-based fecal occult blood test (gFOBT) in most guidelines because FIT is more sensitive, more specific, does not require dietary restrictions, and needs only one sample instead of three. If your doctor orders a 'stool blood test,' it should be a FIT, not a gFOBT.
What is Cologuard and how is it different from FIT?
Cologuard is the brand name for a multi-target stool DNA test (mt-sDNA), manufactured by Exact Sciences. It combines a FIT component (hemoglobin detection) with molecular assays that detect specific DNA mutations and methylation markers shed by colorectal cancers and advanced adenomas into the stool. It also measures a DNA quantity marker that increases when more cells are being shed from the colon lining.
The pivotal study for Cologuard (DeeP-C study, published in NEJM by Imperiale et al., 2014) enrolled nearly 10,000 average-risk adults aged 50 to 84. Cologuard detected 92.3% of colorectal cancers, compared to 73.8% for the FIT component alone. For advanced adenomas, Cologuard detected 42.4% versus 23.8% for FIT. So Cologuard is meaningfully more sensitive than FIT for both cancers and precancerous lesions.
The trade-off is specificity. In the DeeP-C study, Cologuard had a false positive rate of about 13.2%, compared to about 5 to 7% for FIT. That means roughly 1 in 8 people with a positive Cologuard result will have a follow-up colonoscopy that finds no cancer and no advanced adenoma. This is not medically dangerous (colonoscopy complications are rare), but it means unnecessary procedures, time, expense, and anxiety for some patients.
Cologuard is recommended every 3 years if negative, compared to annually for FIT. The collection process is more involved. You provide an entire bowel movement in a special container, add a preservative, and ship it in a provided box. It is not difficult, but it is more of a production than a FIT kit.
How does colonoscopy compare as a screening tool?
Colonoscopy is the gold standard for colorectal cancer screening and the only modality that combines detection with treatment in a single procedure. A gastroenterologist inserts a flexible scope through the entire colon under sedation, visually inspecting the lining for polyps, masses, or other abnormalities. If polyps are found, they are typically removed during the same procedure (polypectomy), which prevents them from ever becoming cancer.
For average-risk adults with a normal result, screening colonoscopy is recommended every 10 years. The long interval reflects the slow progression of colorectal neoplasia: most polyps take 10 to 15 years to progress from adenoma to carcinoma (the adenoma-carcinoma sequence).
Colonoscopy sensitivity for colorectal cancer is estimated at 95% or higher. For adenomatous polyps 10mm or larger, sensitivity is approximately 95%. For smaller polyps (6 to 9mm), sensitivity drops to approximately 75 to 85%, and for very small polyps under 6mm, it can be lower. The NordICC trial, published in NEJM in 2022 by Bretthauer et al., provided the first randomized evidence for colonoscopy screening. On an intention-to-treat basis, the invitation to colonoscopy screening reduced CRC incidence by 18% over 10 years. Among those who actually underwent the procedure (per-protocol analysis), the reduction was 31%.
Colonoscopy is not without downsides. It requires bowel preparation (typically a large-volume laxative solution the day before), sedation with associated recovery time, and a day away from work or normal activities. Serious complications are uncommon but real: perforation occurs in roughly 4 per 10,000 screening colonoscopies, and significant bleeding after polypectomy occurs in about 8 per 10,000.
What do ACS and USPSTF guidelines recommend for colorectal cancer screening?
Both the American Cancer Society (ACS, updated 2018) and the U.S. Preventive Services Task Force (USPSTF, updated 2021) recommend that average-risk adults begin colorectal cancer screening at age 45. Both previously recommended starting at age 50. The change was driven by the rising incidence of colorectal cancer in adults aged 45 to 49 and modeling data suggesting a favorable benefit-to-harm ratio for earlier screening.
Both organizations endorse multiple screening modalities. The USPSTF lists several options with an 'A' grade (recommended with high certainty of substantial net benefit): colonoscopy every 10 years, annual FIT, Cologuard (mt-sDNA) every 1 to 3 years, and CT colonography every 5 years. The ACS similarly supports multiple options but emphasizes that for individuals who choose a non-colonoscopy test, any positive result must be followed up with a timely colonoscopy.
â ī¸A positive FIT or Cologuard result is not a diagnosis of cancer. Most positive results are not cancer. But every positive stool-based test needs a follow-up colonoscopy. Ignoring a positive result, or repeating the stool test instead of getting a colonoscopy, can delay diagnosis of a treatable condition.
Who needs screening before age 45?
The age-45 recommendation is for average-risk adults with no personal or family history of colorectal cancer or polyps, no genetic syndrome, and no inflammatory bowel disease (ulcerative colitis or Crohn's disease involving the colon). Several groups should begin screening earlier.
- People with a first-degree relative (parent, sibling, or child) diagnosed with CRC or advanced adenoma before age 60: guidelines generally recommend colonoscopy starting at age 40, or 10 years before the youngest affected relative's age at diagnosis, whichever is earlier.
- People with Lynch syndrome or other hereditary CRC syndromes: screening with colonoscopy, often starting at age 20 to 25, with intervals as short as every 1 to 2 years depending on the specific mutation.
- People with inflammatory bowel disease (UC or Crohn's colitis): surveillance colonoscopy typically starting 8 years after diagnosis of pancolitis.
- People with a personal history of colorectal polyps: follow-up intervals depend on the number, size, and histology of prior polyps.
- People with persistent, unexplained GI symptoms (rectal bleeding, prolonged change in bowel habits, unexplained iron deficiency anemia): these warrant diagnostic workup regardless of age, which may include colonoscopy.
What about false positives and what happens after an abnormal result?
False positives are inherent to any screening test. For FIT, the false positive rate is approximately 4 to 6%. For Cologuard, it is approximately 13%. A false positive means the test flagged something (blood or DNA markers) that, upon follow-up colonoscopy, turns out not to be cancer or an advanced polyp. Common benign causes include hemorrhoids, diverticulosis, non-advanced polyps, or colitis.
The consequence of a false positive is an unnecessary colonoscopy. For most people, this is an inconvenience and a source of anxiety, not a serious harm. But it is worth understanding, especially when comparing FIT and Cologuard. Over 10 years of screening, the higher false positive rate of Cologuard means that a larger proportion of users will undergo at least one colonoscopy that finds nothing actionable, compared to annual FIT users.
On the other hand, a false negative (a test that misses an existing cancer or polyp) is the more dangerous error. FIT misses about 26% of cancers in a single round, though annual repetition narrows this gap considerably. Cologuard misses about 8% of cancers. Colonoscopy misses about 5%, primarily flat or right-sided lesions that are harder to visualize.
How much does screening cost and is it covered by insurance?
Under the Affordable Care Act, most private insurance plans are required to cover recommended colorectal cancer screening with no out-of-pocket cost when performed at the guideline-recommended intervals. This applies to FIT, Cologuard, and screening colonoscopy. Medicare covers screening colonoscopy every 10 years for average-risk beneficiaries age 45 and older (the age was lowered from 50 in 2023) and Cologuard every 3 years.
There is an important catch. If polyps are found and removed during a screening colonoscopy, the procedure can be reclassified as 'diagnostic' or 'therapeutic,' which may trigger cost-sharing under some insurance plans. The No Surprises Act and subsequent CMS guidance have addressed some of these billing issues, but coverage gaps persist for some patients. The cost of colonoscopy without insurance ranges from roughly $1,500 to $4,000 depending on the facility and anesthesia charges. FIT tests typically cost $20 to $50 out of pocket, and Cologuard is approximately $600 to $700 without insurance.
What helps when you are deciding which screening to choose?
The most important screening test is the one you actually do. A completed FIT is better than a colonoscopy appointment you keep putting off. That said, risk factors matter. If you have a family history of colorectal cancer, Lynch syndrome, or IBD, colonoscopy is generally the recommended modality because it allows direct visualization and polypectomy. For average-risk adults with no family history, FIT or Cologuard are reasonable first-line options, especially if you prefer noninvasive testing.
If you have persistent GI symptoms that concern you, bringing organized symptom notes to your provider can help frame the conversation about whether screening (or diagnostic) colonoscopy makes sense. Tools like GLP1Gut can help you document symptoms over time so you are bringing data, not just impressions, to that appointment.
Whatever you choose, the key is consistency. FIT works best when done every year. Cologuard works best when repeated on schedule every 3 years if negative. And no stool test replaces the need for colonoscopy when results are positive.
The bottom line on colorectal cancer screening options
FIT, Cologuard, and colonoscopy are all effective screening tools, each with trade-offs in sensitivity, specificity, cost, convenience, and invasiveness. Current guidelines support starting at age 45 for average-risk adults, with earlier screening for those at higher risk due to family history, genetics, or inflammatory bowel disease. The screening landscape will continue to evolve as blood-based tests and improved stool tests enter the market, but the fundamental message will not change: screening works, and the best time to start is when the guidelines say you are due.
Can I use Cologuard instead of a colonoscopy if I have a family history of colon cancer?
Guidelines generally recommend colonoscopy (not stool-based tests) as the primary screening tool for people with a significant family history of colorectal cancer or advanced polyps. Stool tests are designed for average-risk screening. Talk to your doctor about the right modality for your specific family history.
What happens if my FIT or Cologuard comes back positive?
A positive result means the test detected blood or abnormal DNA markers in your stool. The next step is always a follow-up colonoscopy. Most positive results are not cancer, but all of them need to be investigated. Do not repeat the stool test or ignore the result.
Are blood-based colorectal cancer tests reliable?
Blood-based tests (like Shield by Guardant Health) are emerging but currently have lower sensitivity than stool-based tests and colonoscopy. The Shield test demonstrated 83.1% sensitivity for CRC in its pivotal trial but only 13.2% for advanced adenomas. Regulatory approval and guideline inclusion are ongoing.